Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer

Journal of Clinical Oncology

Volumn 14, Issue 8, 1996, Pages 2311-2315

  Patt, Y Z ^a   Jones Jr , D V ^a   Hoque, A ^a   Lozano, R ^a   Markowitz, A ^a   Raijman, I ^a   Lynch, P ^a   Charnsangavej, C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; FLUOROURACIL; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; ASTHENIA; BILE DUCT CARCINOMA; BILIARY TRACT DRAINAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; GALLBLADDER CARCINOMA; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT INDICATION;

EID: 0029830677     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.8.2311     Document Type: Article

References (27)

1. Boring CC, Squires TS, Tong T, et al: Cancer statistics, 1994. CA 44:7-26, 1994
2. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. CA 45:8-30, 1995
3. Klatskin G: Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. Am J Med 38:241-256, 1965
4. Renshaw K: Malignant neoplasms of extrahepatic biliary ducts. Ann Surg 76:205-221, 1922
5. Altemeier WA, Gall EA, Zinninger MM, et al: Sclerosing carcinoma of the major intrahepatic bile ducts. Arch Surg 75:450-461, 1957
6. Anthony PP: Tumors and tumor-like lesions of the liver and biliary tract, in MacSwean RNM, Anthony PP, Scheuer PJ (eds): Pathology of the Liver. (ed 2) Edinburgh, United Kingdom, Churchill Livingstone, 1987, pp 574-645
7. Tsuda H, Satarug S, Bhudhisawasdi V, et al: Cholangiocarcinomas in Japanese and Thai patients: Difference in etiology and incidence of point mutation of the c-Ki-ras proto-oncogene. Mol Carcinogen 6:266-269, 1992
8. Crooke ST, Bradner WT: Mitomycin-C: A review. Cancer Treat Rev 3:121-139, 1976
9. Von Eyben F, Hellekant C, Mattson M, et al: Mitomycin-C in advanced gallbladder carcinoma. Acta Radiol Oncol 19:81-84, 1980
10. Falkson G, MacIntyre JM, Moertel CG: Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 54:965-969, 1984
11. Haskell CM: Cancer of the liver, in Haskell CM (ed): Cancer Treatment. Philadelphia, PA, Saunders, 1980, pp 319-324
12. Davis HL Jr, Ramirez G, Ansfield FJ: Adenocarcinoma of stomach, pancreas, liver and biliary tracts: Survival of 328 patients treated with fluoropyrimidine therapy. Cancer 33:193-197, 1974
13. Adolphson CC, Carpenter JT Jr: Response to doxorubicin and mitomycin in cholangiocarcinoma: A case report. Cancer Treat Rep 66:209-210, 1982
14. Bukowski RM, Leichman LP, Rikin SE: Phase II trial of m-AMSA in gallbladder and cholangiocarcinoma: A Southwest Oncology Group study. Eur J Cancer Clin Oncol 6:721-723, 1983
15. Bodey GP, Bedikian AY, Valdivieso M, et al: Chemotherapeutic management of hepatobiliary and pancreatic cancer, in Stroehlein JR, Romsdahl MM (eds): Gastrointestinal Cancer. New York, NY, Raven, 1981, pp 279-292
16. Harvey JH, Smith FP, Schein PS: 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 2:1245-1248, 1984
17. Hall SW, Benjamin RS, Murphy WK, et al: Adriamycin, BCNU, ftorafur chemotherapy of pancreatic and biliary tract cancer. Cancer 44:2008-2013, 1979
18. Ravry MJR, Hester M: Phase II study of Adriamycin plus bleomycin for the treatment of hepatocellular and biliary tract carcinoma. Proc Am Assoc Cancer Res, Proc Am Soc Clin Oncol 20:415, 1979 (abstr 513)
19. Patt YZ, Yoffe B, Chamsangavej C, et al: Low serum alpha fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5 FU and interferon alpha 2b. Cancer 72:2574-2582, 1993
20. Miller HB, Hoogstraten B, Staguet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
21. Snedecor GW, Cohran WG: Statistical Methods (ed 7). Ames, IA, Iowa State University, 1980, pp 73-78
22. Kaplan EL, Meier P: Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
23. Gehan EA: A generalized Wilcoxon test for comparing arbitrarily single censored samples. Biometrics 52:203-223, 1965
24. Whittington R, Neuberg D, Tester WJ, et al: Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: A phase I Eastern Cooperative Oncology Group Trial. J Clin Oncol 13:227-232, 1995
25. Ahlgren JD: Neoplasms of the hepatobiliary system, in Calabresi P, Schein PS (eds): Medical Oncology (ed 2). New York, NY, McGraw-Hill, 1993, pp 713-739
26. Kajanti M, Pyrhönen S: Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system: A phase II study. Am J Clin Oncol 17:223-226, 1994
27. Tempero M, Hansen S, Enke C, et al: Chemoradiotherapy followed by orthotopic liver transplantation (OLT) for unresectable cholangiocarcinoma (ChCA). Proc Am Soc Clin Oncol 14:193, 1995 (abstr 449)